| Literature DB >> 25689740 |
Vincent de Kemp1, Petra de Graaf1, Joost O Fledderus2, J L H Ruud Bosch1, Laetitia M O de Kort1.
Abstract
BACKGROUND: Techniques to treat urethral stricture and hypospadias are restricted, as substitution of the unhealthy urethra with tissue from other origins (skin, bladder or buccal mucosa) has some limitations. Therefore, alternative sources of tissue for use in urethral reconstructions are considered, such as ex vivo engineered constructs.Entities:
Mesh:
Year: 2015 PMID: 25689740 PMCID: PMC4331084 DOI: 10.1371/journal.pone.0118653
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Search strategy and selection of the studies for the present review (n = 44).
The database search was performed on 5 November 2013 according to the PRISMA statement [4]. For more details on the search strategy see Methods section.
Studies investigating autologous cells (n = 18).
| First author (year) | Cell type | Duration of culture |
|---|---|---|
| Fossum (2003) [ | Urothelium | Confluence of primary culture by day 13–21. Third generation culture obtained by day 20–28 |
| Fossum (2005) [ | Urothelium: Long-term culture: urothelium derived from bladder lavages of pediatric patients or short-term culture: urothelium isolated from adult urethra of gender reassignment patients. Feeder cells: immortalized mouse fibroblasts (3T3). Keratinocytes from normal donor skin | Long term culture: Cultured until senescence or until cell morphology did not reveal urothelial phenotype and absence of cytokeratins on immunoassay. Short term culture: 14 days |
| Nagele (2008) [ | Urothelium acquired from bladder washings | n/a |
| Bharadwaj (2011) [ | Urine-derived stem cells from upper urinary tract | n/a |
| Bharadwaj (2013) [ | Urine-derived stem cells from upper urinary tract | n/a |
| Lang (2013) [ | Urine-derived stem cells (USC) | 3 weeks |
| Zhang (2008) [ | Cells obtained from spontaneously voided or catheterized urine | n/a |
| Shi (2012) [ | Adipose-derived stem cells (HADSCs) | 14 days |
| Zhang (2013) [ | Adipose-derived stem cells (ADSCs) and immortalized cell line from urothelium of human urinary bladder (SV-HUC-1) | 2 and 4 weeks |
| Hudson (2007) [ | Urothelium, surgically obtained from renal pelvis, ureter or urinary bladder | n/a |
| Marcovich (2003) [ | Urothelium (UC) and smooth muscle cells (SMC) | Up to 12 days |
| Frimberger (2006) [ | Cells from SDEC-cell line (human embryonic germ cells); Commercially available urothelium (URO) and bladder smooth muscle cells (SMCs) | 8 days |
| Koskela (2009) [ | Urothelium | n/a |
| Fossum (2004) [ | Urothelial cells (UC), smooth muscle cells (SMCs) and fibroblasts (FB) | UCs grown for 1 week, seeding of FBs on the UCs, after another week SMCs seeded on top. Co-culture is incubated for 3 weeks |
| Cattan (2011) [ | Dermal fibroblasts (DF) and urothelium (HUC) | 14 days |
| Imbeault (2013) [ | Dermal fibroblasts (DF), urothelium (UC) and umbilical vein endothelial cells (EC) | n/a |
| Bhargava (2004) [ | Normal human buccal mucosa (keratinocytes and fibroblasts) on donor de-epidermized skin | Up to 14 days |
| Pilatz (2005) [ | Cavernosal tissue | Primary culture, until confluent |
n/a, not applicable
Studies investigating scaffolds and cell-seeded scaffolds (n = 19).
| First author (year) | Cell type | Scaffold type |
|---|---|---|
| Yang (2010) [ | - | Porcine bladder acellular matrix (BAM) |
| Scriven (2001) [ | Normal human urothelium | Hyaluronic acid derivatives (membrane/non-woven mesh); Alginate (non-woven mesh); Chitosan (non-woven mesh); Polyglactin 910 (woven mesh/knitted mesh/knitted mesh modified); PDS/Polyglactin composite (mesh); PSA/Prolene composite (mesh); Zenoderm |
| Bisson (2002) [ | Normal human urothelium | Unmodified PET films; PET surfaces grafted with 0.2 or 5.9 μg/cm2 PAA or PET surfaces grafted with PAA and collagen or albumin (control) immobilized |
| Sartoneva (2010) [ | Normal human urothelium | Human amniotic membrane (hAM) or synthetic poly-L-lactide-co-ε-caprolactone (PLCL) |
| Sartoneva (2012) [ | Normal human urothelium | Different subtypes of PLCL (smooth, textured) and a composite of compression molded and knitted PLA mesh |
| Kundu (2011) [ | Commercially available immortalized benign human bladder urothelial cells (TEU-2) | Composite scaffolds consisting of electrospun fibrous PCL or PLLA onto thin polymer films of PCL or PLLA compared to small intestine submucosa (SIS) |
| Scriven (1997) [ | Normal human urothelium (samples from bladder, renal pelvis and ureter from 5 patients) | De-epithelialized urothelial organ culture (0.5–1.0 cm2), derived from biopsy during surgery for benign conditions |
| Sabbagh (1998) [ | RT112, derived from a well-differentiated transitional cell carcinoma or UROtsa, an immortalized urothelial cell line | Collagen sponge, 95% type I collagen and 5% type III |
| Davis (2011) [ | Commercially available normal human urothelium (HUC) | Porcine small intestine submucosa (SIS) or porcine urinary bladder matrix (UBM) |
| Davis (2011) [ | Commercially available normal human urothelium (HUC) | Porcine urinary bladder matrix (UBM) |
| Rohman (2007) [ | Normal human urothelium (NHU) and smooth muscle cells (SMC) | Spin-coated poly(lactide-co-glycolide) (PLGA) and poly(e-caprolactone) (PCL), both thick and thin films |
| Kimuli (2004) [ | Normal human urothelium (NHU), smooth muscle cells (SM) or invasive bladder cancer cells (EJ-cell line) | Permacol, a commercially available biomaterial developed from porcine dermis by the enzymatic and chemical removal of cellular components, to leave a cross-linked collagen and elastin-rich matrix |
| Zhang (2000) [ | Normal human urothelium (UCs) and smooth muscle cells (SMCs) | Commercially available small intestinal submucosa (SIS) disks, able to be seeded on both sides at once |
| Lakshmanan (2005) [ | Cells from SDEC-cell line (human embryonic germ cells) subculture 7 to 9 used. Human urothelium (URO) and human bladder smooth muscle cells (SMCs) | Small intestinal submucosa (SIS) |
| Wu (2011) [ | Urine-derived stem cells, differentiated in urothelial cells and smooth muscle cells or UC and SMC isolated from normal human ureter | Small intestinal submucosa (SIS) |
| Liu (2009) [ | Normal human urothelium (UC) and bladder smooth muscle cells (SMC) | Porcine bladder submucosa (BSM) |
| Falke (2003) [ | Normal human corpus cavernosal smooth muscle cells (SMCs) and human endothelial cells (ECs) | Collagen matrix obtained from decellularized corpus cavernosum of New Zealand White rabbits |
| Kershen (2002) [ | Human corpus cavernosum smooth muscle cells (SMCs) | Non-woven sheets of polyglycolic acid polymer meshes of >95% porosity were fashioned into 22 tubular rods, 1.0 × 1.0 cm. Interfiber distances of 0–200 μm, fiber diameter 15 μm |
| Park (1999) [ | Human corporal smooth muscle and endothelial cells (ECV 304) | Unwoven 1.0 × 1.0 × 0.3 cm sheets of polyglycolic acid polymer mesh, 15 μm fibers, porosity >95% before seeding |
| Selim (2010) [ | Human keratinocytes and fibroblasts from buccal mucosa biopsy | Polylactide-co-glycolide (PLGA) |
Results of clinical studies using TE techniques (n = 6).
| First author (year) | No. of patients | Cell type | Scaffold(s) | Urethral pathology | Follow-up (months) | Results |
|---|---|---|---|---|---|---|
| El-Kassaby (2003) [ | 28 | n/a | Human bladder acellular matrix | Anterior strictures | 36–48 (mean 37) | Successful in 24/28 patients after first attempt; successful in 4/28 patients after 1 urethrotomy |
| Le Roux (2005) [ | 9 | n/a | Porcine small intestinal submucosa (SIS) | Bulbar strictures | 12 and 24 | Successful in 2/8 patients (after 12–24 months); unsuccessful in 6/8 patients (strictures within 3 months); 1 patient lost during follow-up |
| El-Kassaby (2008) [ | 30 | n/a | Human acellular bladder matrix (ABM) | Complex anterior strictures | 18–36 (mean 25) | Comparative study between repair with BM or ABM. 15/15 patients in BM group had successful outcome, 11/15 patients in ABM group had successful outcome. Poor outcome was related to previous interventions |
| Bhargava (2008) [ | 5 | Normal human buccal mucosa (keratinocytes and fibroblasts) | Donor de-epidermized dermis (DED) | Strictures secondary to lichen sclerosis: 3 panurethral strictures, 2 panbulbar strictures | 32–37 (mean 34) | Without intervention successful in 0/5 patients. 1 patient had total graft excision, 1 patient partial removal of the TEBM graft. After intervention, successful in 4/5 patients (see |
| Raya-Rivera (2011) [ | 5 | Normal human urothelium (UC) and bladder smooth muscle cells (SMC) | Polyglycolic acid meshes (PGA) | Boys with complete posterior urethral disruption (3/5), Boys with failed previous posterior urethral repair (2/5) | 36–76 (mean 64) | Successful in 4/5 patients at first attempt. One additional procedure (urethrotomy) in 1/5 patients |
| Fossum (2012) [ | 6 | Normal human urothelium (UC) from bladder washings | Acellular dermis | Boys with scrotal or perineal hypospadia | 72–103 (mean 86) | Successful in 5/6 patients at first attempt. One additional procedure (urethrotomy) in 1/6 patients. Satisfactory cosmetic appearance in 6/6 patients |
n/a, not applicable